肌酐与胱抑素C及两者比值在肾脏疾病中的研究进展

Research Progress of Creatinine, Cystatin C, and Their Ratio in Renal Diseases

肌酐/胱抑素C比值(CCR)作为一种新兴的生物标志物,在评估肾功能方面备受关注。本综述旨在系统性地总结CCR与肾功能的关系,探讨其在临床实践中的应用和意义。首先,我们介绍了肌酐和胱抑素C作为肾功能指标的基本特点,并分析了传统肌酐测定方法存在的局限性。随后,我们深入探讨了胱抑素C作为一种新型生物标志物的优势,以及CCR作为评估肾功能的新方法。接着,我们综述了近年来关于肌酐/胱抑素C比值在不同临床情境下的应用,包括慢性肾病、急性肾损伤和肾移植评估。最后,我们讨论了CCR在肾功能评估中的潜在影响,以及未来研究的方向。综合而言,CCR作为一种新兴的生物标志物,在评估肾功能方面具有潜在的临床应用前景,但仍需要进一步的研究和验证来确定其在临床实践中的准确性和可靠性。

The creatinine-cystatin C ratio (CCR) has garnered significant attention as an emerging biomarker in the assessment of renal function. This review aims to systematically summarize the relationship between CCR and renal function, and explore its applications and significance in clinical practice. Firstly, we introduce creatinine and cystatin C as fundamental indicators of renal function and analyze the limitations of traditional creatinine measurement methods. Subsequently, we delve into the advantages of cystatin C as a novel biomarker and discuss CCR as a new approach for evaluating renal function. Furthermore, we review the recent applications of CCR in various clinical contexts, including chronic kidney disease, acute kidney injury, and renal transplant evaluation. Finally, we discuss the potential impact of CCR on renal function assessment and outline future research directions. In conclusion, CCR shows promising clinical prospects as an emerging biomarker for assessing renal function, but further research and validation are required to determine its accuracy and reliability in clinical practice.